Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nordefrin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.52 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.52 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | RECQL | P46063 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levonordefrin SCHEMBL6295856 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Levonordefrin SCHEMBL14478222 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Levonordefrin SCHEMBL14478226 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Nordefrin SCHEMBL29693041 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Levonordefrin SCHEMBL29410156 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Levonordefrin SCHEMBL119171 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Levonordefrin SCHEMBL1780761 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Nordefrin SCHEMBL316522 | 0.98 | KDM4E (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Levonordefrin SCHEMBL363800 | 0.98 | KDM4E (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Nordefrin SCHEMBL5060952 | 0.98 | KDM4E (1.00) | TDP1KDM4ERECQLMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 904 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024249843-A2 | GUANFACINE FOR FATIGUE DISORDERS | VANDERBILT UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240225978-A1 | METHODS AND COMPOSITIONS FOR PHARMACOLOGICAL TREATMENT OF BLEPHAROPTOSIS | Bokman, Christine Lynn (US) | 2024-07-11 | — | — | US | claimed |
| CN-117100901-A | Photoinitiated biological tissue adhesive, gel sheet, preparation method and application | 艾弈医疗科技(上海)有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-110143886-B | Process for the preparation of beta-arylaminoalkols such as tulobuterol, chlorpropaline, isoadrenaline dichloride and sotalol | 北京化工大学 | 2022-11-01 | — | — | CN | claimed |
| WO-2020210889-A1 | DYE COMPOSITION FOR MARKING ORGANIC TISSUE WITH ANAESTHETIC AND METHOD FOR APPLYING SAME | HEXSEL, DORIS MARIA (BR) | 2020-10-22 | — | — | WO | claimed |
| EP-3434271-B1 | USE OF PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF POIKILODERMA OF CIVATTE | HEXSEL DORIS MARIA (BR) | 2020-08-26 | — | — | EP | claimed |
| US-10751303-B2 | Method for shortening anti-infective therapy duration in subjects with infection | INSTITUTE FOR CLINICAL PHARMACODYNAMICS, INC. (US) | 2020-08-25 | — | — | US | claimed |
| US-10617688-B2 | Use of pharmaceutical composition for the treatment of skin erythema in poikilodermas | NOVA SCIENTIFICA LLC | 2020-04-14 | — | — | US | claimed |
| US-20190269680-A1 | USE OF AN ACTIVE SUBSTANCE IN THE TREATMENT OF MELASMA | HEXSEL DORIS MARIA (BR) | 2019-09-05 | — | — | US | claimed |
| EP-3498299-A1 | COMPOSITIONS AND METHODS FOR TREATING PURPURA | Aclaris Therapeutics, Inc. (US) | 2019-06-19 | — | — | EP | claimed |
| US-20020068754-A1 | Combination of adrenergic agonist and aryl-cyclo-alkanolamine for relieving chronic pain without adverse side effects | OLNEY JOHN W (US) | 2002-06-06 | — | — | US | claimed |
| US-6369114-B1 | Administration of an α2-adrenergic receptor agonist to enhance cardiopulmonary resuscitation | INSTITUTE OF CRITICAL CARE MEDICINE | 2002-04-09 | — | — | US | claimed |
| US-20020016319-A1 | Combined adamantane derivative and adrenergic agonist for relief of chronic pain without adverse side effects | OLNEY JOHN W (US) | 2002-02-07 | — | — | US | claimed |
| WO-2001089448-A2 | COMBINATION OF ADRENERGIC AGONIST AND NMDA ANTAGONIST FOR RELIEVING CHRONIC PAIN WITHOUT ADVERSE SIDE EFFECTS | OLNEY JOHN W (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001039761-A1 | ADMINISTRATION OF AN ALPHA-2 ADRENERGIC RECEPTOR AGONIST TO ENHANCE CARDIOPULMONARY RESUSCITATION | INSTITUTE OF CRITICAL CARE MEDICINE (US) | 2001-06-07 | — | — | WO | claimed |
| US-5605911-A | NEUROTOXIC SIDE EFFECT INHIBITION | WASHINGTON UNIVERSITY (US) | 1997-02-25 | — | — | US | claimed |
| WO-1994000432-A1 | ANORECTIC EPINEPHRINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-01-06 | — | — | WO | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| EP-0059057-A1 | Treatment of diarrhoea | BEECHAM GROUP PLC (GB) | 1982-09-01 | — | — | EP | claimed |
| US-4313956-A | Novel sypathomimetic amine prodrugs | INTERX RESEARCH CORP. (US) | 1982-02-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10751303-B2 | Method for shortening anti-infective therapy duration in subjects with infection | POLR1C, POLI, TYMP | ADRA2A 4125/4885ADRA2C 4257/4885ADRA2B 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.